UP!

BCR $331.24   View long term graphs

C. R. Bard, Inc.
Type
Public
Traded as NYSE: BCR
S&P 500 Component
Founded 1907
Founder Charles Russell Bard
Headquarters New Providence, New Jersey, U.S.
Area served
Worldwide
Key people
Timothy M. Ring
(Chairman) & (CEO)
Products Vascular, Urology, Oncology, and Surgical Specialties
Revenue IncreaseUS$2.72B (FY 2010)
Operating income
IncreaseUS$730M (FY 2010)
Net income
IncreaseUS$509M (FY 2010)
Total assets IncreaseUS$3.17B (FY 2010)
Total equity DecreaseUS$1.63B (FY 2010)
Number of employees
14,000 (2015)
Website www.crbard.com

C. R. Bard, Inc., now branded simply as Bard, headquartered in Murray Hill, New Jersey, USA, is a leading multinational developer, manufacturer, and marketer of medical technologies in the fields of vascular, urology, oncology, and surgical specialties.

In April 2017, the company has announced that it will be acquired by Becton Dickinson.

Bard markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities. An S&P 500 company with approximately 14,000 employees in 2015, Bard is perhaps best known for having introduced the Foley catheter in 1934. In 2013, Bard began negotiations to settle nearly 30,000 legal claims related to implantable vaginal meshes made by the company.

C. R. Bard, Inc. was founded in New York City by Charles R. Bard in 1907. Bard's first business involved importing Gomenol, which was used to treat urinary discomfort. The company formally incorporated in 1923, and three years later, in 1926, Charles R. Bard sold the company to John F. Willits and Edson L. Outwin for $18,000. Under Willits and Outwins, the company expanded into the catheter business, introducing the Foley catheter in 1934 and the America Woven Catheter in 1940.

In 1948, Bard's annual sales topped $1 million for the first time, and the company moved its headquarters from New York City to Summit, New Jersey. In 1954, a Bard scientist, Dr. DeBakey, developed the first arterial prosthesis. Three years later the company began selling Foley catheters that came in sterile packaging for the first time ever. Bard continued to innovate in the world of catheters, rolling out the Bipolar Temporary Pacing catheter in 1958 and the first latex balloon catheter in 1960. In 1961, Bard expanded beyond catheters, and began manufacturing products related to cardiology, radiology, and anesthesiology.

Bard went public in 1963 and was listed on the New York Stock Exchange in 1968. The company has introduced a variety of new health care products since that time. Its net sales first exceeded $1 billion in 1994. Around 2012, Bard acquired the company Lutonix.

On April 23, 2017, it was announced that Bard would be bought by Becton Dickinson for $24 billion.

Bard specializes in the manufacturing of vascular, urology, oncology and surgical specialty products.

In 2013, Bard agreed to pay $48.26 million to resolve kickback allegations filed against the company, relating to submitting false claims to Medicare. The complaint, filed in 2006, alleges Bard paid illegal kickbacks to both physicians and consumers.

Vaginal mesh devices are threaded into the vagina to treat incontinence or to fortify pelvic muscles. Some women have charged that the devices "are poorly designed and contain materials that are unsafe for use in humans [and that] some require multiple surgeries to remove." In 2012 the U.S. Food and Drug Administration requested that Bard and other vaginal-mesh makers study rates of organ damage linked to the mesh devices. In 2013, Bard began negotiations to settle nearly 30,000 legal claims related to implantable vaginal meshes made by the company. In August 2015 it was announced that Bard had agreed to pay more than $200 million to resolve at least 3,000 of the legal cases related to the devices. The settlement resolves about one-fifth of the outstanding suits related to the implants. Bard said in court filings its devices are "safe and effective."

An Inferior vena cava filter, or more simply, a blood clot filter, is a device that is surgically placed in the vena cava artery to prevent blood clots from moving into the heart or lungs, which can be fatal. On December 31, 2015, NBC News released information about an investigation that they had conducted of the Bard G2 series filters which had replaced an earlier version, the Recovery filter. Introduced in 2002, the Recovery filter was associated with 27 deaths and several hundred non-fatal problems, and "a confidential study commissioned by Bard showed that the Recovery filter had higher rates of relative risk for death, filter fracture and movement than all of its competitors." However, according to the NBC report, the G2 series filters were a modified version of the Recovery filter and Bard was aware that it had "similar and potentially fatal flaws" shortly after it was put on the market. But instead of recalling the replacement filters, they were kept on the market for five years. According to Bard and FDA records, at least 12 deaths and hundreds of problems have been linked to the G2 series filters.

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2017 2018-01-29 Future report Set alerts
Q4 2017 2018-01-29 Future report Set alerts
Q2 2017 2017-07-27 2.92 1.86
Q1 2017 2017-04-23 2.87 2.37
Q4 2016 2017-01-26 2.77 2.11
Q3 2016 2016-10-25 2.64 1.27
Q2 2016 2016-07-26 2.54 2.11
Q1 2016 2016-04-27 2.34 1.54
Q4 2015 2016-01-28 2.43 1.79
Q3 2015 2015-10-22 2.28 -1.16

Ratings

2016-07-08 Downgrade Bank of America Corp. Buy to Neutral
2016-05-25 Reiterated Rating Leerink Swann Hold
2016-05-24 Boost Price Target Barclays Equal Weight $212.00 to $224.00
2016-05-24 Reiterated Rating Piper Jaffray Buy $241.00
2016-05-24 Reiterated Rating Needham & Company LLC Hold
2016-05-24 Reiterated Rating Piper Jaffray Cos. Buy $241.00
2016-05-24 Boost Price Target Barclays PLC Equal Weight $212.00 to $224.00
2016-05-23 Reiterated Rating Bank of America Buy
2016-05-23 Reiterated Rating Bank of America Corp. Buy
2016-05-22 Reiterated Rating Morgan Stanley Hold
2016-04-28 Boost Price Target Barclays Equal Weight $195.00 to $212.00
2016-04-28 Reiterated Rating Needham & Company LLC Hold
2016-03-30 Boost Price Target Leerink Swann Market Perform $196.00 to $205.00
2016-03-17 Initiated Coverage Nomura Neutral $205.00
2016-03-17 Initiated Coverage Nomura Holdings Inc. Neutral $205.00
2016-02-10 Reiterated Rating Deutsche Bank Hold
2016-02-10 Reiterated Rating Deutsche Bank AG Hold
2016-01-31 Reiterated Rating Deutsche Bank Hold
2016-01-29 Lower Price Target Goldman Sachs Buy $214.00 to $211.00
2016-01-29 Lower Price Target Goldman Sachs Group Inc. Buy $214.00 to $211.00
2016-01-27 Boost Price Target JMP Securities Market Outperform $207.00 to $215.00
2015-11-12 Initiated Coverage Citigroup Inc. Buy $220.00
2015-10-23 Reiterated Rating Brean Capital Hold
2015-10-23 Reiterated Rating William Blair Hold
2015-10-23 Reiterated Rating Needham & Company LLC Hold
2015-10-23 Lower Price Target Leerink Swann Market Perform $192.00 to $190.00
2015-10-23 Lower Price Target JMP Securities Market Outperform $220.00 to $207.00
2015-09-10 Boost Price Target JMP Securities Market Outperform $200.00 to $220.00
2015-08-27 Initiated Coverage KeyBanc Sector Weight
2015-08-27 Upgrade Goldman Sachs Neutral to Buy $193.00 to $220.00
2015-08-27 Initiated Coverage KeyCorp Sector Weight
2015-07-23 Reiterated Rating Brean Capital Hold
2015-04-26 Reiterated Rating Brean Capital Hold
2015-04-24 Boost Price Target Barclays Equal Weight $175.00 to $185.00
2015-04-24 Upgrade Bank of America Underperform to Buy $200.00
2015-01-30 Reiterated Rating Jefferies Group Hold $145.00 to $170.00
2015-01-30 Boost Price Target Barclays Equal Weight $150.00 to $175.00
2015-01-30 Boost Price Target JMP Securities Market Outperform $162.00 to $186.00
2015-01-30 Reiterated Rating Brean Capital Hold
2015-01-20 Upgrade JPMorgan Chase & Co. Underweight to Neutral $162.00 to $178.00
2015-01-05 Downgrade JPMorgan Chase & Co. Neutral to Underweight $156.00 to $162.00
2015-01-05 Upgrade Morgan Stanley Underweight to Equal Weight $187.00
2014-12-22 Initiated Coverage Wells Fargo & Co. Market Perform
2014-12-22 Initiated Coverage Wells Fargo Market Perform
2014-07-29 Downgrade Bank of America Neutral to Underperform $150.00
2014-07-25 Reiterated Rating Raymond James Outperform $155.00 to $170.00
2014-07-25 Reiterated Rating Jefferies Group Hold $139.00 to $145.00
2014-07-25 Reiterated Rating JPMorgan Chase & Co. Neutral $142.00 to $156.00
2014-07-25 Reiterated Rating Citigroup Inc. Neutral $147.00 to $153.00
2014-07-25 Reiterated Rating Raymond James Financial Inc. Outperform $155.00 to $170.00
2014-06-20 Downgrade S&P Equity Research Buy to Hold $145.00 to $150.00
2014-06-18 Downgrade Barclays Overweight to Equal Weight $155.00 to $150.00
2014-06-13 Reiterated Rating Deutsche Bank Hold $138.00 to $146.00
2014-06-03 Reiterated Rating Morgan Stanley Positive to Underweight $120.00 to $127.00
2014-04-07 Downgrade Bank of America Buy to Neutral $150.00
2014-03-10 Upgrade Ned Davis Research Neutral to Buy
2014-03-06 Boost Price Target Barclays Overweight $150.00 to $160.00
2014-02-24 Upgrade Ned Davis Research Neutral to Buy
2014-01-09 Boost Price Target Barclays Overweight $140.00 to $150.00
2014-01-08 Upgrade Atlantic Securities Neutral to Overweight $118.00 to $148.00
2014-01-06 Downgrade JPMorgan Chase & Co. Overweight to Neutral $142.00
2013-11-01 Boost Price Target Raymond James Outperform $140.00 to $150.00
2013-10-23 Boost Price Target JPMorgan Chase & Co. Overweight $126.00 to $142.00
2013-10-23 Boost Price Target JMP Securities Market Outperform $130.00 to $140.00
2013-10-23 Boost Price Target Jefferies Group Hold $105.00 to $136.00
2013-10-23 Boost Price Target Cowen and Company Market Perform $102.00 to $123.00
2013-10-23 Boost Price Target BMO Capital Markets Market Perform $115.00 to $122.00
2013-10-23 Boost Price Target Barclays Overweight $135.00 to $140.00
2013-10-23 Upgrade Piper Jaffray Neutral to Overweight $114.00 to $140.00
2013-10-23 Upgrade Goldman Sachs Sell to Neutral $106.00 to $132.00
2013-10-14 Reiterated Rating Citigroup Inc. Neutral $123.00 to $124.00
2012-10-24 Reiterated Mizuho Neutral $93 to $88
2012-02-23 Initiated Northland Securities Market Perform $105
2011-09-16 Initiated Rodman & Renshaw Mkt Perform
2011-02-01 Downgrade Morgan Joseph Buy to Hold
2016-07-08 Downgrade Bank of America Corp. Buy to Neutral
2016-05-25 Reiterated Rating Leerink Swann Hold
2016-05-24 Boost Price Target Barclays Equal Weight $212.00 to $224.00
2016-05-24 Reiterated Rating Piper Jaffray Buy $241.00
2016-05-24 Reiterated Rating Needham & Company LLC Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
DOLCH GARY D Sr. VP-Quality and Reg Affairs 0.04%  (27466) BCR /
KELLY BRONWEN K VP - Human Resources 0.03%  (24704) BCR /
BRESLAWSKY MARC C 0.02%  (12655) BCO / BCR /
Christian Patricia G VP -Quality, Reg & Med Affairs 0.01%  (9239) BCR /

Comments